<DOC>
	<DOCNO>NCT00199979</DOCNO>
	<brief_summary>The study compare immuno-virological efficacy , safety , daily antiretroviral combination ( tenofovir + lamivudine + nevirapine ) versus twice daily association ( fix dose combination zidovudine/lamivudine + nevirapine ) ARV-Naive HIV-1 infected subject , CD4 cell count 350/µL 15 % , whatever viral load . Pharmacological ( nevirapine concentration ) virologic data ( resistance mutation case failure ) also provide , well adherence rate quality life respect treatment arm .</brief_summary>
	<brief_title>Zidovudine / Lamivudine + Nevirapine Twice Daily , Versus Tenofovir + Lamivudine + Nevirapine Once Daily ARV-Naive Patients</brief_title>
	<detailed_description>96-week antiviral efficacy tenofovir + lamivudine + nevirapine , daily , versus reference antiretroviral treatment give twice daily ( zidovudine/lamivudine + nevirapine )</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIV1 infection , confirm westernblot assay , least 6 month primary infection Age &gt; equal 18 year age No prior antiretroviral treatment Karnofsky superior 60 % CD4 T cell &lt; 350/µL ( 2 measure , least 1month interval ) woman , study propose CD4 cell count 250/µL , nevirapine liver toxicity increase ( X10 ) CD4 &gt; 250/µL Written inform consent HIV2 infection coinfection Prior antiretroviral treatment Intolerance , contraindication investigational drug Pregnant breastfeed woman , plan become pregnant Active untreated opportunistic infection ( AIDSdefining illness , category C , CDC , 1993 ) , malignancy require cytotoxic chemotherapy Biological criterion : hemoglobin &lt; 10 G/DL , neutrophil count &lt; 1000/µL , platelet &lt; 50000/µL , creatinine &gt; 2N , ASAT ALAT &gt; 2.5N , bilirubin &gt; 2N , hypophosphatemia Prevision poor adherence HBC coinfection ( Ag Hbs positive ) HVC coinfection ( positive HCV PCR ) Liver failure , alcohol abuse Treatment administration recommend investigational drug Interferon , interleukin , HIV vaccine treatment Informed consent obtain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Antiretroviral Therapy</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>HIV Viral Load</keyword>
	<keyword>Adherence</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Resistance Mutations</keyword>
</DOC>